ECSP19050049A - Anticuerpos anti-ox40 y sus usos - Google Patents

Anticuerpos anti-ox40 y sus usos

Info

Publication number
ECSP19050049A
ECSP19050049A ECSENADI201950049A ECDI201950049A ECSP19050049A EC SP19050049 A ECSP19050049 A EC SP19050049A EC SENADI201950049 A ECSENADI201950049 A EC SENADI201950049A EC DI201950049 A ECDI201950049 A EC DI201950049A EC SP19050049 A ECSP19050049 A EC SP19050049A
Authority
EC
Ecuador
Prior art keywords
antibodies
manufacture
present disclosure
methods
nucleic acids
Prior art date
Application number
ECSENADI201950049A
Other languages
English (en)
Inventor
Fiona A Harding
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of ECSP19050049A publication Critical patent/ECSP19050049A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente divulgación provee anticuerpos anti-OX40 novedosos, composiciones que incluyen los anticuerpos, ácidos nucleicos que codifican para los anticuerpos, y métodos para su elaboración y para su uso.
ECSENADI201950049A 2016-12-15 2019-07-12 Anticuerpos anti-ox40 y sus usos ECSP19050049A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662434761P 2016-12-15 2016-12-15

Publications (1)

Publication Number Publication Date
ECSP19050049A true ECSP19050049A (es) 2019-07-31

Family

ID=60937946

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201950049A ECSP19050049A (es) 2016-12-15 2019-07-12 Anticuerpos anti-ox40 y sus usos

Country Status (36)

Country Link
US (7) US10556962B2 (es)
EP (2) EP3504242B1 (es)
JP (2) JP6772385B2 (es)
KR (2) KR20210157471A (es)
CN (1) CN110573527A (es)
AR (1) AR110526A1 (es)
AU (1) AU2017377036B2 (es)
BR (2) BR112019012328A2 (es)
CA (1) CA3045940A1 (es)
CL (1) CL2019001646A1 (es)
CO (1) CO2019007288A2 (es)
CR (1) CR20190330A (es)
CY (1) CY1123274T1 (es)
DK (1) DK3504242T3 (es)
DO (1) DOP2019000165A (es)
EC (1) ECSP19050049A (es)
ES (1) ES2813057T3 (es)
HR (1) HRP20201259T1 (es)
HU (1) HUE050399T2 (es)
IL (1) IL267070A (es)
LT (1) LT3504242T (es)
MA (1) MA53184A (es)
MX (1) MX2019007121A (es)
MY (1) MY198059A (es)
PE (1) PE20191403A1 (es)
PH (1) PH12019501357A1 (es)
PL (1) PL3504242T3 (es)
PT (1) PT3504242T (es)
RS (1) RS60664B1 (es)
RU (1) RU2753493C2 (es)
SG (1) SG10201914126RA (es)
SI (1) SI3504242T1 (es)
TW (1) TWI734879B (es)
UA (1) UA125041C2 (es)
UY (1) UY37523A (es)
WO (1) WO2018112346A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019012328A2 (pt) * 2016-12-15 2019-11-19 Abbvie Biotherapeutics Inc anticorpos anti-ox40 e seus usos
BR112019025913A2 (pt) * 2017-06-09 2020-06-30 Glaxosmithkline Intellectual Property Development Limited métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira.
WO2019028182A2 (en) * 2017-08-01 2019-02-07 Remd Biotherapeutics, Inc. TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体
WO2020119789A1 (en) * 2018-12-14 2020-06-18 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
WO2020132857A1 (zh) * 2018-12-25 2020-07-02 杭州翰思生物医药有限公司 抗ox40的单克隆抗体及其应用
CN110172090B (zh) * 2019-06-03 2020-04-03 中山标佳生物科技有限公司 Cd134单克隆抗体及其制备方法和癌症治疗中的应用
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
CN113045654A (zh) * 2019-12-27 2021-06-29 南开大学 抗ox40抗体及其用途
CN111303285B (zh) * 2019-12-27 2023-06-02 百力司康生物医药(杭州)有限公司 靶向ox40的抗体及其制备方法和应用
WO2021190431A1 (zh) * 2020-03-23 2021-09-30 百奥泰生物制药股份有限公司 一种免疫细胞激活剂的开发及应用
US20230295324A1 (en) * 2020-06-30 2023-09-21 Harbour Biomed (Shanghai) Co., Ltd Ox40-targeted antibody, and preparation method therefor and application thereof
CN111704671B (zh) * 2020-08-19 2020-11-24 广东赛尔生物科技有限公司 Ox40抗体及其在治疗癌症中的应用
CN112442121A (zh) * 2020-08-20 2021-03-05 山东兴瑞生物科技有限公司 Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用
CN114106173A (zh) * 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
CN111763258B (zh) * 2020-09-01 2020-12-29 北京百奥赛图基因生物技术有限公司 抗ox40抗体及其用途
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
AU2873999A (en) 1998-02-24 1999-09-06 Sisters Of Providence In Oregon Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
US6632926B1 (en) 1998-11-18 2003-10-14 Genentech, Inc. Antibody variants
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2489004C (en) 2002-06-13 2013-01-08 Crucell Holland B.V. Agonistic binding molecules to the human ox40 receptor
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2007084559A2 (en) 2006-01-13 2007-07-26 Board Of Regents, The University Of Texas System Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
AU2008338591B8 (en) 2007-12-14 2014-02-20 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
PE20131403A1 (es) 2010-08-23 2014-01-10 Univ Texas Anticuerpos anti-ox40 y metodos de uso de los mismos
KR101685262B1 (ko) * 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
ES2699599T3 (es) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Variantes de Fc
MD20180107A2 (ro) * 2013-03-18 2019-06-30 Biocerox Products B.V. Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
JP6588461B2 (ja) 2014-03-31 2019-10-09 ジェネンテック， インコーポレイテッド 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
AU2015343339A1 (en) * 2014-11-03 2017-06-15 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an OX40 agonist treatment
US10259882B2 (en) * 2015-05-07 2019-04-16 Agenus Inc. Anti-OX40 antibodies
EP3298045A1 (en) * 2015-05-21 2018-03-28 Alligator Bioscience AB Novel polypeptides
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
EP3383914A4 (en) 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHODS OF USE
BR112019012328A2 (pt) * 2016-12-15 2019-11-19 Abbvie Biotherapeutics Inc anticorpos anti-ox40 e seus usos

Also Published As

Publication number Publication date
DK3504242T3 (da) 2020-08-17
UA125041C2 (uk) 2021-12-29
AU2017377036B2 (en) 2022-06-23
KR102341926B1 (ko) 2021-12-23
CR20190330A (es) 2019-12-19
HUE050399T2 (hu) 2020-12-28
TW201825520A (zh) 2018-07-16
CL2019001646A1 (es) 2019-08-23
MY198059A (en) 2023-07-31
US10556962B2 (en) 2020-02-11
EP3504242A1 (en) 2019-07-03
WO2018112346A1 (en) 2018-06-21
RU2019121895A (ru) 2021-01-15
SI3504242T1 (sl) 2020-10-30
EP3504242B1 (en) 2020-06-24
US20180346593A1 (en) 2018-12-06
CY1123274T1 (el) 2021-12-31
MX2019007121A (es) 2020-02-05
JP2020504101A (ja) 2020-02-06
UY37523A (es) 2018-07-31
AR110526A1 (es) 2019-04-10
CO2019007288A2 (es) 2019-08-20
EP3725809A1 (en) 2020-10-21
TWI734879B (zh) 2021-08-01
JP6772385B2 (ja) 2020-10-21
BR122020025629B1 (pt) 2022-05-31
CA3045940A1 (en) 2018-06-21
US20220112304A1 (en) 2022-04-14
JP2021019603A (ja) 2021-02-18
PL3504242T3 (pl) 2020-11-16
IL267070A (en) 2019-08-29
RS60664B1 (sr) 2020-09-30
US20180171023A1 (en) 2018-06-21
BR112019012328A2 (pt) 2019-11-19
RU2019121895A3 (es) 2021-02-15
PE20191403A1 (es) 2019-10-04
CN110573527A (zh) 2019-12-13
SG10201914126RA (en) 2020-02-27
US10604584B2 (en) 2020-03-31
MA53184A (fr) 2021-05-26
KR20190092552A (ko) 2019-08-07
US10040864B2 (en) 2018-08-07
US20180194855A1 (en) 2018-07-12
LT3504242T (lt) 2020-09-10
KR20210157471A (ko) 2021-12-28
ES2813057T3 (es) 2021-03-22
PH12019501357A1 (en) 2020-01-20
US20200181282A1 (en) 2020-06-11
HRP20201259T1 (hr) 2020-11-13
PT3504242T (pt) 2020-08-26
US20210017289A1 (en) 2021-01-21
RU2753493C2 (ru) 2021-08-17
US20200048363A1 (en) 2020-02-13
DOP2019000165A (es) 2019-07-15
AU2017377036A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
ECSP18094829A (es) Anticuerpos anti-cd40 y sus usos
NI201800055A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos.
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CO2018000244A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
ECSP17023281A (es) Inhibidores de mk2 y sus usos
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
CR20150462A (es) Inhibidores de erk y sus usos
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
CR20190271A (es) Anticuerpos antitau y métodos de uso
CO2017011238A2 (es) Anticuerpos anti-c1s humanizados
CL2017001461A1 (es) Composiciones y métodos para anticuerpos que se marcan bmp6
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CO2019013718A2 (es) Anticuerpos anti-trkb
BR112018010596A2 (pt) anticorpos para cgrp e usos dos mesmos